RXP470.1

RXP470.1 (RXP-470) is a potent, selective MMP-12 inhibitor with a Ki of 0.2 nM against human MMP-12. RXP470.1 is 2 to 4 orders of magnitude less potent against other MMPs. RXP470.1 significantly reduces atherosclerotic plaque cross-sectional area in mouse. RXP470.1 results in less complex plaques with increased smooth muscle cell:macrophage ratio, less macrophage apoptosis, increased cap thickness, smaller necrotic cores, and decreased incidence of calcification[1].

Product Specifications

CAS Number

[891198-31-5]

Product Name Alternative

RXP-470

UNSPSC

12352005

Target

MMP

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/rxp470-1.html

Purity

99.60

Solubility

10 mM in DMSO

Smiles

O=P(O)(C1=CC=C(Br)C=C1)C[C@H](C(N[C@@H](CCC(O)=O)C(N[C@H](C(N)=O)CCC(O)=O)=O)=O)CC2=CC(C3=CC=C(C4=CC(Cl)=CC=C4)C=C3)=NO2

Molecular Formula

C35H35BrClN4O10P

Molecular Weight

818.00

References & Citations

[1]Jason L Johnson, et al. A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol. 2011 Mar;31 (3) :528-35.